Do we have sufficient evidence in 2009 to decide whether to implant biventricular pacemaker or cardioverter-defibrillator to cardiac resynchronization therapy patients?
Authors:
M. Táborský; P. Neužil
Authors place of work:
Kardiocentrum, Nemocnice Na Homolce, Praha
Published in the journal:
Kardiol Rev Int Med 2009, 11(1): 16-19
Summary
Do we have sufficient evidence in 2009 to decide whether to implant biventricular pacemaker or cardioverter-defibrillator to cardiac resynchronization therapy patients? Cardiac resynchronization therapy represents one of the standard non‑pharmacological treatment of severe heart failure in patiens with significant left ventricle dysfunction and ventricular dyssynchrony. The choise of device has to consider the potential benefit of the therapy – the comorbidities, the life expectancy but also the cost‑effectiveness and the potential complications related to the device. New devices provide information about the hemodynamical status of this heart failure patient population allowing early detection of heart failure decompensation – for example using home monitoring – avoiding recurrent hospitalisations from this reason. Based on analysis of recent clicinal studies, in 2009 we do not have enough data if for patients with CRT indication is the biventricular ICD better compared to the biventricular pacemaker. The only one exception are patients with end‑stage heart failure, NYHA IV class, where the implant of biventricular pacemaker is preferred.
Keywords:
cardiac resynchronization therapy – heart failure – ICD – pacemaker
Zdroje
1. Táborský M, Kautzner J, Bytešník J et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a srdeční resynchronizační léčbu. Cor Vasa 2005; 47: 59–68.
2. Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation 2008; 117: e350–e408.
3. Cazeau S, Leclercq C, Lavergne T et al. Effects on multisite biventricular Pacing in patiens with heart failure and intraventricular delay. N Eng J Med 2001; 344: 873–880.
4. Auricchio A, Stellbrink C, Sack S et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF). J Am Coll Cardiol 2002; 39: 2026–2033.
5. Bristow MR, Saxon LA, Boehmer J et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. N Engl J Med 2004; 350: 2140–2150.
6. Abraham WT, Fischer WG, Smith AL et al. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization therapy. N Engl J Med 2002; 346: 1845–1853.
7. Cleland JG, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Sudy Investigators. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Eng J Med 2005; 352: 1539–1549.
8. Cleland JG, Daubert JC, Erdmann E et al. Longer‑term effects of cardiac resynchronization therapy on mortality in heart failure. Eur Heart J 2006; 27: 1928–1932.
9. Flather MD, Yusuf S, Køber et al. Long‑term ACE‑inhibitor therapy in patiens with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patiens. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575–1581.
10. The MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–2007.
11. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patiens with severe heart failure. N Engl J Med 1999; 341: 709–717.
12. Pitt B, Remme W, Zannad F et al. Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. N Engl J Med 2003; 348: 1309–1321.
13. Linde C, Leclercq C, Rex S et al. Long‑term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111–118.
14. Kuck KH, Cappato R, Siebels J et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–754.
15. Connolly SJ, Gent M, Roberts RS. Canadian Implantable Defibrillator Study (CIDS) a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297–1302.
16. AVID Inestigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patiens resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576–1583.
17. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization therapy and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685–2694.
18. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patiens with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933–1940.
19. Buton AE, Lee KL, DiCarlo L et al. Electrophysiologic testing to identify patiens with coronary artery disease who are at risk for sudden cardiac death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342: 1937–1945.
20. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patiens with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.
21. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of a implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481–2488.
22. Bardy GH, Lee KL, Mark DB et al. Sudden Cardiac death in Heart Failure Trial (SCD-HeFT) Trial. N Engl J Med 2005; 352: 225–237.
23. Strickberger SA, Hummel JD, Bartlett TG et al. AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patiens with non‑ischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia – AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707–1712.
24. Bänsch D, Antz M, Boczor S et al. Primary prevention of sudden cardaic death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002; 105: 1453–1458.
25. Yu CM, Wang L, Chau E et al. Intrathoracic impedance monitoring in patiens with heart failure: correlation with fluid status and feasibility of early warning preding hospitalization. Circulation 2005; 112: 841–848.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2009 Číslo 1
Najčítanejšie v tomto čísle
- Ischemia-reperfusion injury following cardiac arrest and protective effects of hypothermia
- Surgical treatment of atrial fibrillation
- Current issues in resynchronization therapy of patients with heart failure
- Do we have sufficient evidence in 2009 to decide whether to implant biventricular pacemaker or cardioverter-defibrillator to cardiac resynchronization therapy patients?